

**Remarks**

Claims 1-35 were pending. Due to the restriction requirement, claims 2-7, 9, 26-28 and 30-35 are cancelled without prejudice to prosecution in a future divisional application. No claims are added. Therefore, claims 1, 8, 10-25 and 29 are now pending.

Applicants elect Group I (claims 1-25 and 29) and the 143 mutations or polymorphisms listed in Table 1 (pages 73-74 of the application). The claims are amended to reflect this election by incorporating original claim 5 into claims 1 and 22, and cancelling claims 2-7, 9.

No amendments are made to distinguish prior art and no new matter is introduced by this amendment.


If there are any questions regarding this response, the Examiner is invited to telephone the undersigned.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By

  
Sheree Lynn Ryba, PhD.  
Registration No. 47,913